KOREAN DRUG CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name KOREAN DRUG CO., LTD.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 13.5%
- Equity ratio
- 88.1%
- ROE
- 7.8%
- Op. margin
- 11.1%
- Rev. growth
- -14.4%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩180 | 29.9% |
| 2024 | ₩160 | 57.8% |
| 2023 | ₩150 | n/a |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 15.5% | 86.5% | 11.8% | 15.1% | n/a |
| FY2022 separate | 11.6% | 89.6% | 13.9% | 17.9% | 7.4% |
| FY2023 separate | 16.4% | 85.9% | -6.4% | 22.2% | 1.7% |
| FY2024 separate | 13.8% | 87.9% | 3.8% | 12.5% | -10.3% |
| FY2025 separate | 13.5% | 88.1% | 7.8% | 11.1% | -14.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩74.5B | ₩80.0B | ₩81.4B | ₩73.0B | ₩62.5B |
| Operating profit | ₩11.3B | ₩14.3B | ₩18.0B | ₩9.1B | ₩6.9B |
| Pre-tax income | ₩11.3B | ₩14.7B | ₩8.3B | ₩5.0B | ₩7.8B |
| Net income | ₩9.0B | ₩11.8B | -₩4.9B | ₩3.0B | ₩6.5B |
| Total assets | ₩88.6B | ₩94.5B | ₩89.7B | ₩88.9B | ₩94.3B |
| Total liabilities | ₩11.9B | ₩9.8B | ₩12.6B | ₩10.8B | ₩11.2B |
| Total equity | ₩76.7B | ₩84.7B | ₩77.1B | ₩78.1B | ₩83.1B |
| Paid-in capital | ₩5.5B | ₩5.5B | ₩5.5B | ₩5.5B | ₩5.5B |
| Debt/equity (source value) | 15.5% | 11.6% | 16.4% | 13.8% | 13.5% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1980-01-10
- Listed
- 00/12/07
- Employees
- 238
- Auditor
- 대성삼경회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1344110001840
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 고려제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.